Shopping Cart
- Remove All
- Your shopping cart is currently empty
Duligotuzumab is a dual-targeting human IgG1 monoclonal antibody that simultaneously binds to both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). Duligotuzumab exerts its antitumor effects by blocking these dual signaling pathways and by inducing antibody-dependent cellular cytotoxicity (ADCC), targeting tumors where EGFR/HER3 overexpression correlates with poor prognosis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $398 | In Stock | |
5 mg | $1,037 | In Stock | |
10 mg | $1,660 | In Stock |
Description | Duligotuzumab is a dual-targeting human IgG1 monoclonal antibody that simultaneously binds to both epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). Duligotuzumab exerts its antitumor effects by blocking these dual signaling pathways and by inducing antibody-dependent cellular cytotoxicity (ADCC), targeting tumors where EGFR/HER3 overexpression correlates with poor prognosis. |
Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.